Health ❯ Healthcare ❯ Clinical Trials

Obesity Treatments

Tirzepatide Semaglutide GLP-1 Drugs Amycretin MariTide PF-08653944 WVE-007 Eloralintide GLP-1 Receptor Agonists Phase 3 Trials

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA could issue a U.S. decision by March 28 under a faster review timeline, according to Reuters.

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial